Helsinn's anamorelin approval chances plummet on mixed PhIII cachexia data
This article was originally published in Scrip
Executive Summary
Switzerland's Helsinn Group has presented results from two Phase III studies of cachexia drug anamorelin, with which it is planning 2015 filings in the US and Europe. But while the drug hit one of its co-primary endpoints, its failure to hit the second makes its success questionable.